B
Berit Sundberg
Researcher at Karolinska Institutet
Publications - 95
Citations - 13889
Berit Sundberg is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Transplantation & Mesenchymal stem cell. The author has an hindex of 34, co-authored 95 publications receiving 13155 citations. Previous affiliations of Berit Sundberg include Karolinska University Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Katarina Le Blanc,Ida Rasmusson,Berit Sundberg,Cecilia Götherström,Moustapha Hassan,Mehmet Uzunel,Olle Ringdén +6 more
TL;DR: It is postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo and are transplanted in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver.
Journal ArticleDOI
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
Katarina Le Blanc,Francesco Frassoni,Lynne M. Ball,Franco Locatelli,Helene Roelofs,Ian D. Lewis,Edoardo Lanino,Berit Sundberg,Maria Ester Bernardo,Mats Remberger,Giorgio Dini,R. Maarten Egeler,Andrea Bacigalupo,Willem E. Fibbe,Olle Ringdén +14 more
TL;DR: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD.
Journal ArticleDOI
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.
TL;DR: MSC added to PBL cultures had various effects, ranging from slight inhibition to stimulation of DNA synthesis, which was not affected by the MSC dose or by the addition of allogeneic or autologous MSCs to the lymphocytes.
Journal ArticleDOI
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Olle Ringdén,Mehmet Uzunel,Ida Rasmusson,M Remberger,Berit Sundberg,Helena Lönnies,Hanns-Ulrich Marschall,Aldona Dlugosz,Attila Szakos,Zuzana Hassan,Brigitta Omazic,Johan Aschan,L Barkholt,Le Blanc K +13 more
TL;DR: MSC is a very promising treatment for severe steroid-resistant acute GVHD and five patients are still alive between 2 months and 3 years after the transplantation and their survival rate was significantly better than that of 16 patients with steroid- resistant biopsy-proven gastrointestinal GV HD, not treated with MSC during the same period.
Journal ArticleDOI
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.
TL;DR: The findings indicate that MSCs escape recognition by CTLs and alloreactive NK cells, and inhibit the formation of cytotoxic T cells by secreting a soluble factor, but that they do not interfere with C TLs and NK cell lysis.